LA JOLLA, Calif. and SZEGED, Hungary and BUDAPEST, Hungary, July 21, 2020 (GLOBE NEWSWIRE)

CalciMedica, a clinical-stage biotechnology  company  targeting  calcium  release-activated  calcium  (CRAC)channels for the treatment of acute and severe inflammatory diseases, and EpiPharma, a bio-pharmaceuticalservices  and drug development  company,  today  announced  that  they  have  entered  into  a  collaboration agreement to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline. Thecollaboration agreement provides that all rights, title and interest in all results shall be owned by CalciMedica. EpiPharma’s diagnostics and research facilities provide complex services including gene and protein expressionanalysis, histology, immunohistochemistry, immunofluorescent staining, 2D cell culture models, 3D animal andpatient-derived organoid culture models (established from a wide range of organs such as colon, oesophagus,stomach, liver and pancreas, lung, etc.), analysis of signal transduction pathways (such as Ca2+ and cAMPsignalling) and in vitro and in vivo disease modelling."We are delighted to be working with CalciMedica, a leader in the discovery and development of novel CRACchannel inhibitors for the treatment of inflammatory and autoimmune disorders and organ transplant rejection,"said József Maléth, chief scientific officer of EpiPharma. “We believe that the application of our state-of-the-artPre-clinical  Drug  Testing  and  Diagnostics  Laboratory  Platform  to  CalciMedica’s  discovery  and  developmentportfolio will help unlock the potential of its breakthrough drug candidates for major unmet clinical needs.”Ken Stauderman, Ph.D., chief scientific officer of CalciMedica added, “We have been working with József toexamine the role of CRAC channels in pancreatic ductal cell function. Findings from a test with one of our CRACchannel inhibitors (CM5480) in his models showed that it restores function of the ductal cells during experimentalacute pancreatitis. These findings prompted us to collaborate, leveraging the latest technology and combiningresources to speed up the development of our portfolio of highly selective CRAC channel inhibitor drugs that havepotential to improve outcomes for patients with acute inflammatory indications.”

About EpiPharma LLC.

EpiPharma is a privately held bio-pharmaceutical services and drug development company.The  EpiPharma  Group  brings  together  breakthrough  proteomimetic  peptide  chemistry  and  a  state-of-the-artdiagnostic laboratory from gene expression profiling to in vivo disease models.The  EpiPharma  Services  support  clients  and  partners in their  drug  development  programs  and  provide  anunparalleled laboratory research environment for characterizing, testing and evaluating new potential treatmentapproaches.The EpiPharma Drug unit develops Proteomimetic Peptide Drugs to treat major infectious diseases.

About CalciMedica, Inc.

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channeldrug discovery and development for the treatment of acute and severe inflammatory diseases. The Companywas founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey PinesTherapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s workincludes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted byCalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is

developing  to  improve  outcomes  for  patients  with  acute  inflammatory  indications.  It  has  also  assembled  aportfolio of patents and patent applications covering those compounds as well as different aspects of CRACchannel biology. CalciMedica is headquartered in San Diego, CA. For more information, please visit the companywebsite at www.calcimedica.com

‍